gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 08 Dec 2016.

CD33 molecule

CD33
Top mentioned proteins: CD34, CD13, CAN, HAD, CD14
Papers on CD33
CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
New
Impact
Meshinchi et al., Portland, United States. In J Clin Oncol, Feb 2016
PURPOSE: CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO).
Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
New
Walter et al., Saint Louis, United States. In Expert Rev Hematol, Feb 2016
Only the CD33 antibody-drug conjugate gemtuzumab ozogamicin provided benefit in randomized studies.
The influence of myeloid derived suppressor cells on angiogenesis and tumor growth after cancer surgery.
New
Hong et al., Kunming, China. In Int J Cancer, Feb 2016
Here, we demonstrated that human MDSCs expressing CD11b(+) , CD33(+) and HLA-DR(-) significantly increased in lung cancer patients after thoractomy.
Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.
New
Webb et al., Baltimore, United States. In J Immunol, Feb 2016
CD33(+) cells cultured in HNSCC cell line-derived conditioned medium differentiated into myeloid derived suppressor cells (MDSC) (CD33(+)CD11b(+)HLA-DR(-/low)).
Relationship between Alzheimer's disease GWAS-linked top hits and risk of Parkinson's disease with or without cognitive decline: a Chinese population-based study.
New
Guo et al., Changsha, China. In Neurobiol Aging, Jan 2016
To examine whether there is a genetic link for these diseases, we performed a case-control study in Chinese population to evaluate the association of AD genome-wide association studies top hits with both PD and cognitive function in PD, investigating 13 single-nucleotide polymorphisms in 9 genes (BIN1, CLU, ABCA7, CR1, PICALM, MS4A6A, CD33, MS4A4E, and CD2AP).
Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
Review
New
Testa et al., Roma, Italy. In Blood Cells Mol Dis, Dec 2015
Concerning this last point, the most promising therapeutic targets are CD33 and CD123.
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.
Review
New
Kim et al., Ch'unch'ŏn, South Korea. In Biomol Ther (seoul), Nov 2015
The potential approval of an anti-CD22 conjugate and promising new clinical data for anti-CD19 and anti-CD33 conjugates are additional advancements.
Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease.
Review
New
Pocock et al., London, United Kingdom. In Curr Opin Neurobiol, Nov 2015
The findings strongly implicate genes related to the immune response (CR1, CD33, MS4A, CLU, ABCA7, EPHA1 and HLA-DRB5-HLA-DRB1), endocytosis (BIN1, PICALM, CD2AP, EPHA1 and SORL1) and lipid biology (CLU, ABCA7 and SORL1) [2-8], and many encode proteins which are highly expressed in microglia [1].
Update on antigen-specific immunotherapy of acute myeloid leukemia.
Review
New
Walter et al., Seattle, United States. In Curr Hematol Malig Rep, Jun 2015
Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO).
An unusual tumour of the lung.
Review
New
Sellami-Boudawara et al., In Pathologica, Mar 2015
The neoplastic mast cells stained strongly with tryptase, CD117, CD68 and CD45, CD14 and CD33; whereas the undifferentiated cells lacked all these markers and expressed EMA and cytokeratin.
Coexistent t(8;21)(q22;q22) Translocation and 5q Deletion in Acute Myeloid Leukemia.
Minami et al., In J Clin Exp Hematop, 2014
Myeloblasts were positive for CD19 and CD56 as well as CD13, CD33, CD34 and HLA-DR.
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
Impact
Aplenc et al., In J Clin Oncol, 2014
PURPOSE: To improve survival rates in children with acute myeloid leukemia (AML), we evaluated gemtuzumab-ozogamicin (GO), a humanized immunoconjugate targeted against CD33, as an alternative to further chemotherapy dose escalation.
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans.
Impact
Alzheimer Disease Genetics Consortium et al., New York City, United States. In Jama, 2013
Several loci previously associated with Alzheimer disease but not reaching significance in genome-wide analyses were replicated in gene-based analyses accounting for linkage disequilibrium between markers and correcting for number of tests performed per gene (CR1, BIN1, EPHA1, CD33; 0.0005 < empirical P < .001).
Acute myeloid leukemia in first remission: to choose transplantation or not?
Impact
Stone, Boston, United States. In J Clin Oncol, 2013
Bone marrow examination revealed 90% infiltration with myeloid-appearing blasts, and flow cytometry analysis confirmed the diagnosis of acute myeloid leukemia (AML) with expression of CD33, CD13, and CD117.
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.
Impact
Seeger et al., Los Angeles, United States. In J Clin Oncol, 2012
Expression of genes representing TAMs (CD33/CD16/IL6R/IL10/FCGR3) contributed to 25% of the accuracy of a novel 14-gene tumor classification score.
The prevalence of CD33 and MS4A6A variant in Chinese Han population with Alzheimer's disease.
GeneRIF
Chen et al., Shanghai, China. In Hum Genet, 2012
data revealed the allele (T) of the rs3865444 polymorphism of the CD33 gene and the allele (C) of the rs610932 polymorphism of the MS4A6A gene may contribute to Alzheimer's disease risk in the Chinese Han population
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
GeneRIF
Valent et al., Vienna, Austria. In Haematologica, 2012
CD33 is expressed abundantly on immature CD34(+)/CD38(-) stem cells and may serve as a stem cell target in chronic myeloid leukemia.
Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
GeneRIF
Guarini et al., Roma, Italy. In Leuk Lymphoma, 2011
Studies showed the qualitative and quantitative expression of four target surface antigens, CD19, CD20, CD22, and CD33, for which MoAbs are currently available for clinical use, in ALL.
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.
Impact
GeneRIF
Williams et al., Cardiff, United Kingdom. In Nat Genet, 2011
found independent evidence for association for Alzheimer's disease susceptibility loci at EPHA1, CD33 and CD2AP
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
Impact
GeneRIF
Schellenberg et al., Miami, United States. In Nat Genet, 2011
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
share on facebooktweetadd +1mail to friends